Reynolds Risk Score for Women
Predicts 10-year cardiovascular event risk in women ≥ 45 years without prior CVD, adding hsCRP and family history to traditional risk factors.
Score interpretation
Reynolds Risk < 5%: Low risk for major cardiovascular events over 10 years.
→ Lifestyle modification. Annual reassessment of risk factors.
Reynolds Risk 5–9%: Intermediate risk. Consider statin therapy based on LDL levels and other factors.
→ Lifestyle modification. Statin therapy consideration. Discuss aspirin risks/benefits.
Reynolds Risk ≥ 10%: High risk. Statin therapy recommended regardless of LDL level.
→ Statin therapy. Blood pressure control. Smoking cessation. Aspirin if appropriate.
Interpretation bands for the Reynolds Risk. Apply clinical judgement and local guidance.
References
- Ridker PM et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA. 2007;297(6):611-619.
Related
Curated clinical cross-links plus same-class fallbacks.
- Framingham Risk Score · Cardiovascular Risk
- ACC/AHA Pooled Cohort Equations — ASCVD Risk · Cardiovascular Risk
- PREVENT Cardiovascular Risk Calculator (AHA/ACC 2023) · Cardiovascular Risk
- SCORE2 — 10-Year CVD Risk (Age 40–69) · Cardiovascular Risk
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Fluvastatin · HMG-CoA reductase inhibitor (statin)
- Pravastatin sodium · HMG-CoA reductase inhibitor (hydrophilic statin)
- Simvastatin with ezetimibe · HMG-CoA reductase inhibitor + cholesterol absorption inhibitor
- Bempedoic acid with ezetimibe · ATP-citrate lyase inhibitor + cholesterol absorption inhibitor
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.